Mansi Shah, MD
Hematology · New Brunswick, NJNPI 1548689763
Payments from drug & device makers
Across 422 payments — averaging $4102.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$978K
- Janssen Research & Development, LLC$477K
- Bristol Myers Squibb$83K
- AbbVie$79K
- Johnson & Johnson$79K
- E.r. Squibb & Sons, L.L.C.$11K
- plus $24K from 12 others
Across 50 payments — averaging $299.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$15K
What the payments were for
- Consulting fees$42,54432%
- Speaking & faculty fees$67,84152%
- Travel & lodging$16,76913%
- Food & beverage$3,5753%
- Education$3170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 216 | $978,200 |
| Janssen Research & Development, LLC | 67 | $477,094 |
| Bristol Myers Squibb | 6 | $82,640 |
| AbbVie | 4 | $79,462 |
| Johnson & Johnson | 94 | $78,610 |
| E.r. Squibb & Sons, L.L.C. | 9 | $11,002 |
| Regeneron Healthcare Solutions, Inc. | 5 | $10,018 |
| Pfizer | 6 | $5,676 |
| Janssen Global Services, LLC | 2 | $4,100 |
| Janssen Scientific Affairs, LLC | 3 | $3,865 |
| Seagen Inc. | 3 | $323 |
| Incyte Corporation | 1 | $130 |
| Sanofi | 1 | $71 |
| AstraZeneca | 1 | $43 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Amgen | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Intuitive Surgical | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,731,291 in reported general payments places this provider in the 95th percentile of 43 hematology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 47 | $1,091,658 |
| RevlimidLenalidomide | 42 | $759,981 |
| OnuregAzacitidine | 26 | $585,532 |
| Lenalidomide | 28 | $388,494 |
| EliquisApixaban | 37 | $28,857 |
| Acyclovir | 96 | $1,190 |
| Entecavir | 14 | $997 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $769 |
| Fluconazole | 13 | $669 |
| Ondansetron Hcl | 17 | $446 |
| Gabapentin | 24 | $436 |
| Dexamethasone | 19 | $323 |
| Duloxetine Hcl | 22 | $315 |
| Prochlorperazine Maleate | 15 | $210 |
| Levofloxacin | 21 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $11,002 | $1,677,19073 claims |
| Bristol Myers SquibbRevlimid | $82,640 | $759,98142 claims |
| PfizerEliquis | $5,676 | $28,85737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 hematology providers in New Jersey.
Other hematology in New Brunswick
- Ogechukwu EginiNew Brunswick$89K
- Claire PhilippNew Brunswick$53K
- Joseph EidNew Brunswick$7K
- Xiaoyi ChenNew Brunswick$2K
- Adam ZayacNew Brunswick$724
- Payal SojitraNew Brunswick$186
- Virian SereiNew Brunswick$49
- Shelonitda RoseNew Brunswick$19
- Colleen CiccosantiNew Brunswick$14
- Ahmed GalalMorristown$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.